CClinicalTrials.gg
Sign In
Status unknownNCT00825721Updated Jan 21, 2009

Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract

A Phase 2 interventional study of LiquiTears and C-KAD Ophthalmic Solution in Nuclear Cataract, sponsored by Chakshu Research, Inc.. Status unknown at 1 site in Nepal. Open to participants aged 35 Years to 90 Years. Per ClinicalTrials.gov, last updated 2009-01-21.

Sponsored by Chakshu Research, Inc. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2009), so the status shown — last known as Active, not recruiting — may be out of date.
Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
35 Years to 90 Years
Sex
All
01

Study summary

This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract

02

Conditions studied

  • Nuclear Cataract

Browse trials for

Keywords

  • Cataract Study
  • Ophthalmic Study
  • Agerelated cataract
  • Nuclear Cataract
  • Low grade nuclear cataracts
03

In context

Cataract

1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.

This study's enrollment of 81 is close to the median of 80 across 1,155 interventional studies indexed under Cataract.

Browse Cataract studies →

Lead sponsor

Chakshu Research, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Presence of nuclear sclerosis cataract
  • BCDVA within the range of 20/40 and 20/80

Exclusion criteria

Exclusion Criteria:

  • Any other clinical condition in the eye that may compromise vision
  • Presence or history of glaucoma
  • Presence or history of diabetes
  • Use of eyedrops
  • Use of steroids
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Active comparator
    1.3% (low dose)

    Drug: C-KAD Ophthalmic Solution

  • Active comparator
    2% (medium dose)

    Drug: C-KAD Ophthalmic Solution

  • Active comparator
    2.6% (high dose)

    Drug: C-KAD Ophthalmic Solution

  • Placebo comparator
    Placebo

    Drug: LiquiTears

Interventions

  • DrugLiquiTears

    4 drops applied daily for 360 days

  • DrugC-KAD Ophthalmic Solution

    4 drops applied daily for 360 days

  • DrugC-KAD Ophthalmic Solution

    4 drops applied daily for 360 days

  • DrugC-KAD Ophthalmic Solution

    4 drops applied daily for 360 days

06

What researchers measure

Primary outcomes

  1. Best-corrected visual acuity by ETDRS

    Time frame: 360 days

07

Study locations

1 site
  • Tilganga Eye Center
    Kathmandu, Nepal
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 21, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00825721
Lead sponsor
Chakshu Research, Inc.
First posted
Jan 21, 2009
Start date
Nov 2007
Primary completion
Aug 2009 (estimated)
Completion
Sep 2009 (estimated)
Last update
Jan 21, 2009

Study contacts

Sanduk Ruit, MD
principal investigator · Tilganga Eye Center
Reeta Gurung, MD
principal investigator · Tilganga Eye Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Cataract→

Other studies from this sponsor

Chakshu Research, Inc.

Start the discussion